MRC Agrotech's 163% revenue jump hides a big March problem.
The agri-trader's FY26 revenue tripled, but the auditor flagged that nearly half of it arrived in the final month.
— 1 earlier story on MRC Agrotech Ltd. →What's new
- FY26 standalone revenue surged 163% to ₹85.45 crore from ₹32.44 crore a year earlier.
- The auditor flagged that 45% of total revenue was recognised in the final month of the fiscal year.
- Two related counterparties accounted for 53% of all purchases, and a ₹16.85 cr Marsapi Lifesciences acquisition was consolidated.
Why this matters
The 163% headline growth is undermined by its timing and concentration. Bunching nearly half of the year's revenue into March raises questions about its sustainability and the quality of earnings. For a nano-cap firm, relying this heavily on two related counterparties adds significant operational and related-party risk to the balance sheet.
What we're watching
- Whether Q1 FY27 revenue sustains the pace or normalises after the March spike.
- Any follow-up on the delayed statutory filing and audit reconciliation issues.
- The performance integration of the newly consolidated Marsapi Lifesciences.
The full read
Revenue tripled. Profit turned positive. MRC Agrotech's FY26 numbers look spectacular on the surface, with standalone revenue soaring 163% to ₹85.45 crore and net profit hitting ₹1.16 crore. The audit report tells a different story. 45% of that revenue arrived in March alone. 53% of purchases came from two related counterparties. The company also consolidated a ₹16.85 crore non-cash acquisition of Marsapi Lifesciences. For a nano-cap agri-trader, the growth is real on paper. Its composition is not. The missed filing deadline, blamed on reconciling high-volume trading, doesn't inspire confidence in the underlying controls.
Questions answered
- Why is the auditor concerned about MRC Agrotech's revenue?
- The audit report highlights that 45% of the full year's revenue was booked in just the last month, March. This pattern, combined with high counterparty concentration, raises concerns about the timing and quality of the earnings.
- What is the supplier concentration risk?
- Two related counterparties supplied 53% of all purchases for the year. This extreme reliance on a few entities, which are connected to the company, creates significant operational and related-party risk.
- What was the non-cash acquisition?
- MRC Agrotech consolidated Marsapi Lifesciences through a share-swap agreement valued at ₹16.85 crore. The acquisition also involved a loan assignment agreement with Cicago Commodities.
- Did the company meet its filing deadlines?
- No. The company missed its statutory filing deadline for these audited results, citing audit reconciliation requirements related to a high volume of back-to-back trading transactions.
Story so far
All notes on MRCAGRO →- 3 Jun 2026 · 10:41 AM IST MRC Agrotech's 163% revenue jump hides a big March problem.
- 4d ago MRC Agrotech misses FY26 audit deadline